# Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer

Source: https://onco.cc/trials/nct05735080/  
OnCo record `nct05735080` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Fulvestrant, Abemaciclib in ovarian cancer and metastatic cancer, run by Incyclix Bio, now recruiting.

## Summary

Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer is a phase 1/2 interventional study registered as NCT05735080 by Incyclix Bio, with 150 participants planned, started 2023-03-28 and due to reach its primary completion in 2027-07. Interventions recorded: INX-315, Fulvestrant, Abemaciclib. Conditions listed: Breast Cancer, Breast Cancer Metastatic, Hormone Receptor Positive Tumor, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05735080
- Phase: 1/2
- Setting: A Phase 1/2, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of INX-315 in Patients With Advanced Cancer
- Sponsor: Incyclix Bio
- Enrolled: 150

## Sources

- ClinicalTrials.gov NCT05735080: https://clinicaltrials.gov/study/NCT05735080

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/), [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- drugs: [Abemaciclib](https://onco.cc/drugs/abemaciclib/), [Fulvestrant](https://onco.cc/drugs/fulvestrant/)

---
JSON: https://onco.cc/api/v1/entities/nct05735080.json